Guggenheim Maintains Buy on Kymera Therapeutics, Raises Price Target to $170
Guggenheim analyst Brad Canino maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $135 to $170.
Stocks · News reference
Kymera Therapeutics Says Enrollment Completed In Phase 2b BROADEN2 Trial Of KT-621 In Atopic Dermatitis, With Topline Data Expected By Year-End 2026; Phase 3 Trials Planned To Initiate By Mid-2027
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Wells Fargo Maintains Overweight on Kymera Therapeutics, Raises Price Target to $151
Barclays Maintains Overweight on Kymera Therapeutics, Raises Price Target to $139
Barclays analyst Eliana Merle maintains Kymera Therapeutics (NASDAQ:KYMR) with a Overweight and raises the price target from $133 to $139.